Moleculin Biotech Inc. (NASDAQ: MBRX) released a CEO Corner segment featuring Chief Executive Officer Walter Klemp discussing Annamycin's safety profile, according to a company statement.

Klemp emphasized Annamycin's lack of cardiotoxicity, which distinguishes it from traditional anthracyclines such as doxorubicin that are associated with cardiac damage. The drug was designed to avoid heart-related side effects and has demonstrated this characteristic in preclinical and clinical studies, the company stated.

The non-cardiotoxic profile could expand treatment options for patients with relapsed or refractory acute myeloid leukemia and advanced solid tumors, particularly those previously treated with anthracyclines or patients with existing cardiac risk factors.

Moleculin is currently conducting the MIRACLE Study, a Phase 3 trial evaluating Annamycin in combination with cytarabine for treating relapsed or refractory acute myeloid leukemia. The company describes this as a pivotal, adaptive design trial following a Phase 1B/2 study.

Annamycin, also known as naxtarubicin, is being developed for treating relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company states the drug is designed to avoid multidrug resistance mechanisms common with currently prescribed anthracyclines.

Moleculin also develops WP1066, targeting brain tumors and pancreatic cancers, and maintains a portfolio of antimetabolites including WP1122 for treating pathogenic viruses and certain cancer indications.